Patents by Inventor Florence Mahuteau-Betzer
Florence Mahuteau-Betzer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11739073Abstract: A compound: wherein X1 represents an alkenylene group, a —NH—CO— group, a —CO—NH— group, Y1 represents an aryl group selected from pyridyl, pyrazinyl or pyrimidinyl, X2 represents —O—, —CO—NH—, —NH—CO—NH—, —OCH2—, —NH—CO—, a divalent 5-membered heteroaromatic ring comprising 1 to 4 heteroatoms or —SO2—NH—, and Y2 represents a hydrogen atom, a hydroxyl group, a morpholinyl group, a piperidinyl group, optionally substituted by a (C1-C4)alkyl group, a piperazinyl group, optionally substituted by a (C1-C4)alkyl group, or —CR1R2R3 or alternatively X2—Y2 represents —CONRcRd, wherein Rc and Rd form, together with the nitrogen atom a heterocyclic ring, optionally substituted by one or two (C1-C4)alkyl group, by a cyclopentyl group thus forming a spirocyclopentyl, or by a trifluoromethyl group, or any of its pharmaceutically acceptable salt, for use in the treatment and/or prevention of a RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification.Type: GrantFiled: July 9, 2019Date of Patent: August 29, 2023Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER, INSTITUT CURIEInventors: Didier Scherrer, Jamal Tazi, Florence Mahuteau-Betzer, Romain Najman, Julien Santo, Cécile Apolit
-
Publication number: 20220356175Abstract: A compound of formula (Ic) wherein X2 represents a —CO—NRk— group, wherein Rk represents a hydrogen atom or a methyl group, a —NH—CO—NH— group, a —OCH2— group, a —CH(OH)— group, a —NH—CO— group, a —O— group, a —O—(CH2)s—O—, a —CO— group, a —SO2— group, a divalent 5-membered heteroaromatic ring comprising 1, 2, 3 or 4 heteroatoms, —a NH—SO2— or a —SO2—NH— group; Y2 represents a hydrogen atom, a halogen atom, a hydroxyl group, a (C1-C4)alkoxy group, a a group, a group, a morpholinyl group, optionally substituted by a (C1-C4)alkyl group, a piperazinyl group, a piperidinyl group, or a —CR1R2R3 group, or any of its pharmaceutically acceptable salt.Type: ApplicationFiled: July 9, 2019Publication date: November 10, 2022Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER, INSTITUT CURIEInventors: Didier SCHERRER, Jamal TAZI, Florence MAHUTEAU-BETZER, Romain NAJMAN, Julien SANTO, Cécile APOLIT
-
Patent number: 11441181Abstract: A use of at least one miRNA, said at least one miRNA being miR-124, as a biomarker, in particular of a viral infection, or of an efficacy of a therapeutic treatment of said viral infection.Type: GrantFiled: January 17, 2014Date of Patent: September 13, 2022Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE, UNIVERSITE DE MONTPELLIER, INSTITUT CURIEInventors: Jamal Tazi, Didier Scherrer, Aude Garcel, Noëlie Campos, Romain Najman, Florence Mahuteau-Betzer
-
Publication number: 20210309611Abstract: A compound of formula (I) or any of its pharmaceutically acceptable salt for use in the treatment and/or prevention of a RNA virus infection, and a RNA virus infection from group IV or V of the Baltimore classification wherein R3 represents a chlorine atom or a hydrogen atom, R represents a (C1-C4)alkyl group, a (C3-C6)cycloalkyl group, a halogen atom, a (C1-C5)alkoxy group, a —SO2—NRaRb group, a —SO3H group, a —OH group, a —O—SO2—ORc group or a —O—P(?O)—(ORc)(ORd) group, R1 represents (i) a CF3 group, (ii) a (C1-C10)alkyl group, (iii) a (C3-C6)cycloalkyl or a (C3-C6)heterocycloalkyl group or (iv) a phenyl group or a naphthyl group, and R2 represents a hydrogen atom, a (C1-C10)alkyl group, a (C3-C6)cycloalkyl or a (C3-C6)heterocycloalkyl group and further relates to new compounds, to pharmaceutical compositions containing them and to synthesis process for manufacturing them.Type: ApplicationFiled: July 9, 2019Publication date: October 7, 2021Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER, INSTITUT CURIEInventors: Didier SCHERRER, Jamal TAZI, Florence MAHUTEAU-BETZER, Romain NAJMAN, Julien SANTO, Cécile APOLIT
-
Publication number: 20210300871Abstract: A compound: wherein X1 represents an alkenylene group, a —NH—CO— group, a —CO—NH— group, Y1 represents an aryl group selected from pyridyl, pyrazinyl or pyrimidinyl, X2 represents —O—, —CO—NH—, —NH—CO—NH—, —OCH2—, —NH—CO—, a divalent 5-membered heteroaromatic ring comprising 1 to 4 heteroatoms or —SO2—NH—, and Y2 represents a hydrogen atom, a hydroxyl group, a morpholinyl group, a piperidinyl group, optionally substituted by a (C1-C4)alkyl group, a piperazinyl group, optionally substituted by a (C1-C4)alkyl group, or —CR1R2R3 or alternatively X2—Y2 represents —CONRcRd, wherein Rc and Rd form, together with the nitrogen atom a heterocyclic ring, optionally substituted by one or two (C1-C4)alkyl group, by a cyclopentyl group thus forming a spirocyclopentyl, or by a trifluoromethyl group, or any of its pharmaceutically acceptable salt, for use in the treatment and/or prevention of a RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification.Type: ApplicationFiled: July 9, 2019Publication date: September 30, 2021Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER, INSTITUT CURIEInventors: Didier SCHERRER, Jamal TAZI, Florence MAHUTEAU-BETZER, Romain NAJMAN, Julien SANTO, Cécile APOLIT
-
Publication number: 20210122732Abstract: A compound of formula (Ie): wherein Y1 represents an aryl group, X2 represents a —O— group, a —NH— group, a —S— group, a —CO—NH— group, a —NH—CO—NH— group, a —NH—CO— group, a —CH(OH)— group, a —CH(COOH)NH— group, a —CH(COOCH3)NH— group, a —C(OH)(CH2OH)—, a group, a divalent 5-membered heteroaromatic ring comprising 1, 2, 3 or heteroatoms, a —SO2— group, or a —SO2—NH— group, Y2 represents a hydrogen atom, a hydroxyl group, a (C1-C4)alkoxy group, a —CHC(OH)2, a COORf, wherein Rf represents a hydrogen atom or a (C1-C4)alkyl group, a morpholinyl group, a dihydropyranyl group, a group, a group, a —PO(ORf)(OR?f) group, wherein Rf and R?f independently represents a hydrogen atom or a (C1-C4)alkyl group, an oxetanyl group, a —Si(CH3)3 group, a —NHCOO—(C1-C4)alkyl group, or a —CR1R2R3 group, or any of its pharmaceutically acceptable salt and pharmaceutical compositions containing them and to synthesis process for manufacturing them.Type: ApplicationFiled: July 9, 2019Publication date: April 29, 2021Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER, INSTITUT CURIEInventors: Didier SCHERRER, Jamal TAZI, Florence MAHUTEAU-BETZER, Romain NAJMAN, Julien SANTO, Cécile APOLIT
-
Patent number: 10654813Abstract: Compounds and pharmaceutically acceptable salts thereof that may be used to treat a disease, for example, Duchenne muscular dystrophy, AIDS, and progeria. The compounds and pharmaceutically acceptable salts thereof may be part of a pharmaceutical composition including a pharmaceutically acceptable support.Type: GrantFiled: October 5, 2018Date of Patent: May 19, 2020Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIERInventors: Jamal Tazi, David Grierson, Florence Mahuteau-Betzer, Pierre Roux
-
Publication number: 20190022037Abstract: Compounds and pharmaceutically acceptable salts thereof that may be used to treat a disease, for example, Duchenne muscular dystrophy, AIDS, and progeria. The compounds and pharmaceutically acceptable salts thereof may be part of a pharmaceutical composition including a pharmaceutically acceptable support.Type: ApplicationFiled: October 5, 2018Publication date: January 24, 2019Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIERInventors: Jamal TAZI, David GRIERSON, Florence MAHUTEAU-BETZER, Pierre ROUX
-
Patent number: 10130595Abstract: A method of treating a disease selected from the group consisting of cancer, Duchenne muscular dystrophy, AIDS, and progeria, that includes administering to a patient in need thereof an effective quantity of at least one compound of formula (IV) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: December 3, 2015Date of Patent: November 20, 2018Assignees: CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIERInventors: Jamal Tazi, David Grierson, Florence Mahuteau-Betzer, Pierre Roux
-
Patent number: 9827237Abstract: Methods for preventing or treating retroviral infection not HIV and/or for preventing, inhibiting or treating a disease caused by the retroviral infection include contacting a cell with compound (I) wherein: means a pyridazine, pyrimidine or pyrazine group, R independently represent a hydrogen atom, halogen atom or group chosen among a —CN, hydroxyl, —COOR1, (C1-C3)fluoroalkyl, (C1-C3)fluoroalkoxy, —NO2, —NR1R2, (C1-C4)alkoxy, phenoxy and (C1-C3)alkyl group, the alkyl being optionally mono-substituted by hydroxyl group, n is 1, 2 or 3, n? is 1 or 2, R? is a hydrogen atom, halogen atom or group chosen among (C1-C3)alkyl group, hydroxyl group, —COOR1 group, —NO2 group, —NR1R2 group, morpholinyl or morpholino group, N-methylpiperazinyl group, (C1-C3)fluoroalkyl group, (C1-C4)alkoxy group and —CN group, Z is N or C, Y is N or C, X is N or C, W is N or C, T is N or C, U is N or C.Type: GrantFiled: July 4, 2014Date of Patent: November 28, 2017Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER, INSTITUT CURIEInventors: Jamal Tazi, Florence Mahuteau-Betzer, Romain Najman, Didier Scherrer, Noëlie Campos, Aude Garcel
-
Patent number: 9556489Abstract: The present invention relates to the use (i) of a level of expression of a long RBM39 protein isoform, termed RBM39L, and (ii) of a level of expression of a short RBM39 protein isoform, termed RBM39C, as a marker for the efficacy of an active agent capable of preventing and/or treating HIV infection.Type: GrantFiled: March 4, 2013Date of Patent: January 31, 2017Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.), UNIVERSITE DE MONTPELLIER, INSTITUT CURIEInventors: Jamal Tazi, Julian Venables, Aude Garcel, Noëlle Campos, Florence Mahuteau-Betzer, Romain Najman, Didier Scherrer
-
Publication number: 20160166519Abstract: A method of treating a disease selected from the group consisting of cancer, Duchenne muscular dystrophy, AIDS, and progeria, that includes administering to a patient in need thereof an effective quantity of at least one compound of formula (IV) or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: December 3, 2015Publication date: June 16, 2016Inventors: Jamal TAZI, David GRIERSON, Florence MAHUTEAU-BETZER, Pierre ROUX
-
Publication number: 20160151348Abstract: Methods for preventing or treating retroviral infection not HIV and/or for preventing, inhibiting or treating a disease caused by the retroviral infection include contacting a cell with compound (I) wherein: means a pyridazine, pyrimidine or pyrazine group, R independently represent a hydrogen atom, halogen atom or group chosen among a —CN, hydroxyl, —COOR1, (C1-C3)fluoroalkyl, (C1-C3)fluoroalkoxy, —NO2, —NR1R2, (C1-C4)alkoxy, phenoxy and (C1-C3)alkyl group, the alkyl being optionally mono-substituted by hydroxyl group, n is 1, 2 or 3, n? is 1 or 2, R? is a hydrogen atom, halogen atom or group chosen among (C1-C3)alkyl group, hydroxyl group, —COOR1 group, —NO2 group, —NR1R2 group, morpholinyl or morpholino group, N-methylpiperazinyl group, (C1-C3)fluoroalkyl group, (C1-C4)alkoxy group and —CN group, Z is N or C, Y is N or C, X is N or C, W is N or C, T is N or C, U is N or C.Type: ApplicationFiled: July 4, 2014Publication date: June 2, 2016Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIERInventors: Jamal TAZI, Florence MAHUTEAU-BETZER, Romain NAJMAN, Didier SCHERRER, Noëlie CAMPOS, Aude GARCEL
-
Patent number: 9233931Abstract: The present invention relates to a compound of one of the formulas I to XXI; a pharmaceutical composition comprising at least one such compound; and the use of at least one such compound in preparing a drug to treat, in a subject, a genetic disease resulting from at least one splicing anomaly.Type: GrantFiled: November 4, 2013Date of Patent: January 12, 2016Assignees: CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUESInventors: Jamal Tazi, David Grierson, Florence Mahuteau-Betzer, Pierre Roux
-
Publication number: 20150361491Abstract: A use of at least one miRNA, said at least one miRNA being miR-124, as a biomarker, in particular of a viral infection, or of an efficacy of a therapeutic treatment of said viral infection.Type: ApplicationFiled: January 17, 2014Publication date: December 17, 2015Inventors: Jamal TAZI, Didier SCHERRER, Aude GARCEL, Noëlie CAMPOS, Romain NAJMAN, Florence MAHUTEAU-BETZER
-
Publication number: 20150072892Abstract: The present invention relates to the use (i) of a level of expression of a long RBM39 protein isoform, termed RBM39L, and (ii) of a level of expression of a short RBM39 protein isoform, termed RBM39C, as a marker for the efficacy of an active agent capable of preventing and/or treating HIV infection.Type: ApplicationFiled: March 4, 2013Publication date: March 12, 2015Inventors: Jamal Tazi, Julian Venables, Aude Garcel, Noëlle Campos, Florence Mahuteau-Betzer, Romain Najman, Didier Scherrer
-
Patent number: 8895726Abstract: The present invention relates to a compound derived from indole corresponding to the following formula II: wherein X represents N, CR8 or N+R8, wherein R8 represents a hydrogen atom, a hydroxyl or alkyl or methoxy group optionally substituted with a phenyl group; R2, R3 and R4 independently represent a hydrogen atom or a halogen atom or an optionally substituted alkyl, amine, alkene, ester, sulfonamide, ether or benzyl group; R5 represents a hydrogen atom or an optionally substituted, saturated or unsaturated alkyl group, amine, benzyl group; R6 represents an optionally substituted C1-C3 alkyl group; R7 represents a hydrogen atom or an optionally substituted C1-C3 alkyl group and R7 is absent when the ring A is in the b position, and A represents a ring; R9 and R10 represent together a carbon bond or independently represent an R11 OR11, SR11 group; wherein R11 represents a hydrogen atom, an optionally substituted, saturated or unsaturated, C1-C3 alkyl group, which may contain one or more sulfur, oxygen orType: GrantFiled: February 19, 2008Date of Patent: November 25, 2014Assignees: The Institut Curie, The University of Montpellier 2 Science and TechniquesInventors: Fabrice Lejeune, Jamal Tazi, David Grierson, Christian Rivalle, Florence Mahuteau-Betzer
-
Publication number: 20140155436Abstract: The present invention relates to a compound of one of the formulas I to XXI; a pharmaceutical composition comprising at least one such compound; and the use of at least one such compound in preparing a drug to treat, in a subject, a genetic disease resulting from at least one splicing anomaly.Type: ApplicationFiled: November 4, 2013Publication date: June 5, 2014Applicants: CENTRE NATIONAL DE RECHERCHE SCIENTIFIQUE, UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES, INSTITUT CURIEInventors: Jamal TAZI, David GRIERSON, Florence MAHUTEAU-BETZER, Pierre ROUX
-
Patent number: 8604063Abstract: The present invention relates to a compound of one of the formulas I to XXI; a pharmaceutical composition comprising at least one such compound; and the use of at least one such compound in preparing a drug to treat, in a subject, a genetic disease resulting from at least one splicing anomaly.Type: GrantFiled: January 12, 2009Date of Patent: December 10, 2013Assignees: Centre National de Recherche Scientifique, Institut Curie, Universite Montpellier 2 sciences et TechniquesInventors: Jamal Tazi, David Grierson, Florence Mahuteau-Betzer, Pierre Roux
-
Publication number: 20110053975Abstract: The present invention relates to a compound of one of the formulas I to XXI; a pharmaceutical composition comprising at least one such compound; and the use of at least one such compound in preparing a drug to treat, in a subject, a genetic disease resulting from at least one splicing anomaly.Type: ApplicationFiled: January 12, 2009Publication date: March 3, 2011Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS, INSTITUT CURIE, UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUESInventors: Jamal Tazi, David Grierson, Florence Mahuteau-Betzer, Pierre Roux